Reflecting on Rare Disease Day: ‘Rare’ Does Not Mean ‘Not Real’ - by Kristie Cline
Other updatesA conversation with Sarah, mom to Tyler and Kaitlyn, who are living with a rare disease known as APDS
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.
Pharming Celebrates International Day of Women and Girls in Science - February 11
Other updatesOn February 11, Pharming celebrates the International Day of Women and Girls in Science, which was first declared by the United Nations in 2015 to promote the full and equal access to, and participation of, women and girls in Science, Technology, Engineering and Mathematics (STEM) fields. The day promotes the role of women in scientific fields, promoting those already successful in the field, and aims to inspire more women and girls to pursue careers in science.
Pharming Group to participate in February investor conferences
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February:
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
Financial updatesExpect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end
Patient Shares Journey with APDS on “The Balancing Act” Airing on Lifetime TV - by Kristie Cline
Other updatesThere’s strength in the stories of people living with rare diseases.
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
Clinical trialsInitial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
Clinical trialsThe multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
Corporate updatesPharming Group N.V. announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetable included in the CHMP Day 180 Second LoOI, and considering the CHMP’s decision to reschedule the Ad-Hoc Expert Group (AEG) meeting to the end of November, Pharming now expects the CHMP to issue its opinion on the leniolisib MAA in the first quarter of 2024.
Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Conference attendancePharming Group N.V. announces 14 poster presentations by the Company or its collaborators regarding leniolisib and RUCONEST® at the International Primary Immunodeficiencies Congress (IPIC) and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in November.